Key Takeaways
- Boehringer Ingelheim will launch LENZELTA, a new mastitis vaccine for dairy cattle, in several European Union countries starting April 2026.
- The vaccine targets two key mastitis pathogens, S. aureus and E. coli, and is administered in two doses during the dry-off period.
- LENZELTA offers the earliest onset of immunity and longest lasting protection of bovine mastitis vaccines, providing protection for up to six months.
- Dr. Gerald Behrens, Head of Ruminants at Boehringer Ingelheim, stated the vaccine sets “a new benchmark in mastitis prevention” for the dairy industry.
- The vaccine uses an oil-free adjuvant and comes in multiple vial sizes to provide veterinarians flexibility in daily practice.
Boehringer Ingelheim Addresses Critical Dairy Industry Challenge
Boehringer Ingelheim announced the upcoming launch of LENZELTA, a new vaccine designed to significantly reduce the incidence and severity of clinical mastitis in dairy cattle. The vaccine will become available in several European Union countries beginning in April 2026, targeting one of the most economically significant diseases affecting dairy operations worldwide.
Mastitis continues to represent one of the highest avoidable economic impacts for dairy farms, affecting udder health and reducing both milk quality and quantity. The disease particularly impacts cows around calving time, making preventive strategies during the dry-off period crucial for maintaining herd health and ensuring smooth transitions into lactation.
LENZELTA Vaccine Technology and Administration
The new vaccine targets two primary mastitis pathogens: S. aureus and E. coli. LENZELTA is administered through a simple two-dose protocol during the dry-off period, designed to integrate easily into established herd-health routines. The vaccine provides protection lasting up to six months, covering the period when cows face the highest susceptibility to mastitis infections.
